JP2014522841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522841A5 JP2014522841A5 JP2014519088A JP2014519088A JP2014522841A5 JP 2014522841 A5 JP2014522841 A5 JP 2014522841A5 JP 2014519088 A JP2014519088 A JP 2014519088A JP 2014519088 A JP2014519088 A JP 2014519088A JP 2014522841 A5 JP2014522841 A5 JP 2014522841A5
- Authority
- JP
- Japan
- Prior art keywords
- oil
- item
- water emulsion
- composition
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505109P | 2011-07-06 | 2011-07-06 | |
| US61/505,109 | 2011-07-06 | ||
| US201161545936P | 2011-10-11 | 2011-10-11 | |
| US61/545,936 | 2011-10-11 | ||
| US201261585641P | 2012-01-11 | 2012-01-11 | |
| US61/585,641 | 2012-01-11 | ||
| PCT/US2012/045845 WO2013006837A1 (en) | 2011-07-06 | 2012-07-06 | Cationic oil-in-water emulsions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016156141A Division JP2016210792A (ja) | 2011-07-06 | 2016-08-09 | カチオン性水中油型エマルジョン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522841A JP2014522841A (ja) | 2014-09-08 |
| JP2014522841A5 true JP2014522841A5 (enExample) | 2015-08-20 |
| JP6120839B2 JP6120839B2 (ja) | 2017-04-26 |
Family
ID=46604537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519088A Expired - Fee Related JP6120839B2 (ja) | 2011-07-06 | 2012-07-06 | カチオン性水中油型エマルジョン |
| JP2016156141A Withdrawn JP2016210792A (ja) | 2011-07-06 | 2016-08-09 | カチオン性水中油型エマルジョン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016156141A Withdrawn JP2016210792A (ja) | 2011-07-06 | 2016-08-09 | カチオン性水中油型エマルジョン |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9636410B2 (enExample) |
| EP (2) | EP2729124B1 (enExample) |
| JP (2) | JP6120839B2 (enExample) |
| CN (1) | CN103796639B (enExample) |
| AU (2) | AU2012280904B2 (enExample) |
| BR (1) | BR112014000235A8 (enExample) |
| CA (1) | CA2840965C (enExample) |
| ES (1) | ES2702318T3 (enExample) |
| MX (1) | MX350258B (enExample) |
| RU (1) | RU2649133C2 (enExample) |
| SG (1) | SG10201605500TA (enExample) |
| WO (1) | WO2013006837A1 (enExample) |
Families Citing this family (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| AU2013286093B2 (en) * | 2012-07-06 | 2018-01-04 | Novartis Ag | Complexes of cytomegalovirus proteins |
| US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| AU2014204826A1 (en) | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
| ES2498521B1 (es) * | 2013-02-20 | 2015-08-18 | Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) | Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PL2970948T3 (pl) | 2013-03-15 | 2019-06-28 | Glaxosmithkline Biologicals Sa | Sposoby oczyszczania rna |
| ES2749223T3 (es) | 2013-04-16 | 2020-03-19 | Univ Cincinnati | Composiciones antimicrobianas de antibióticos aminoglicosídicos y quelantes de iones de zinc |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| IL310015B2 (en) * | 2013-12-31 | 2026-02-01 | Access To Advanced Health Inst | Single vial formulation |
| US10842859B2 (en) | 2014-03-25 | 2020-11-24 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| EP3134117A1 (en) * | 2014-04-23 | 2017-03-01 | Institute for Research in Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| US10350165B2 (en) | 2014-12-12 | 2019-07-16 | Ojai Energetics Pbc | Methods and systems for forming stable droplets |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| JP7028774B2 (ja) * | 2015-08-19 | 2022-03-02 | シャンハイ ギンポサム ファーマテック カンパニー リミテッド | ギンセノシドを膜材料として有するリポソームならびにその調製および使用 |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| SG11201803360UA (en) * | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| US20180271970A1 (en) * | 2015-10-22 | 2018-09-27 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| CN107190050B (zh) * | 2016-03-14 | 2020-10-27 | 华东理工大学 | 一种hrp活性测定及h2o2浓度检测的试剂盒及其应用 |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017208191A1 (en) | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| EP3541416A1 (en) | 2016-11-17 | 2019-09-25 | GlaxoSmithKline Biologicals SA | Zika viral antigen constructs |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| US20180216022A1 (en) * | 2017-01-27 | 2018-08-02 | Scott Rettberg | System and method for reducing friction, torque and drag in artificial lift systems used in oil and gas production wells |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| WO2018170270A1 (en) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| AU2018285694B2 (en) * | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| AU2018333530B2 (en) | 2017-09-13 | 2024-05-30 | Biontech Cell & Gene Therapies Gmbh | RNA replicon for expressing a T cell receptor or an artificial T cell receptor |
| US12291717B2 (en) | 2017-09-13 | 2025-05-06 | Biontech Rna Pharmaceuticals Gmbh | RNA replicon for reprogramming somatic cells |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US20190137035A1 (en) | 2017-11-03 | 2019-05-09 | Scott Rettberg | System and method for reducing friction, torque and drag in artificial lift systems used in oil and gas production wells |
| KR20240134250A (ko) | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| AU2019321186B2 (en) | 2018-08-17 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2020144295A1 (en) | 2019-01-10 | 2020-07-16 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| MX2022000879A (es) * | 2019-07-21 | 2022-05-02 | Glaxosmithkline Biologicals Sa | Vacuna viral terapeutica. |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CN110643632B (zh) * | 2019-09-26 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用 |
| EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
| KR102764120B1 (ko) * | 2019-12-31 | 2025-02-06 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| US12569553B2 (en) | 2020-03-09 | 2026-03-10 | Dynavax Technologies Corporation | Shingles vaccines comprising a TLR9 agonist |
| US20230364219A1 (en) | 2020-04-16 | 2023-11-16 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
| JP7769644B2 (ja) | 2020-06-04 | 2025-11-13 | バイオエヌテック エスエー | 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン |
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| AU2021392077A1 (en) * | 2020-12-02 | 2023-07-13 | Seqirus Inc. | Multicistronic rna vaccines and uses thereof |
| EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
| US20240301006A1 (en) | 2020-12-23 | 2024-09-12 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| BR112023022548A2 (pt) * | 2021-04-30 | 2024-01-02 | Samyang Holdings Corp | Kit para preparar nanopartículas contendo fármaco |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| WO2022259191A1 (en) | 2021-06-09 | 2022-12-15 | Glaxosmithkline Biologicals Sa | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| IN202121031414A (enExample) * | 2021-07-13 | 2023-01-13 | ||
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| US20250236883A1 (en) | 2021-10-18 | 2025-07-24 | BioNTech SE | Modified replicable rna and related compositions and their use |
| EP4419708A1 (en) | 2021-10-18 | 2024-08-28 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| CN114316130B (zh) * | 2021-12-27 | 2023-04-25 | 爱森（中国）絮凝剂有限公司 | 工业生产二甲基二烯丙基氯化铵副产氯化钠在阳离子乳液中的利用方法 |
| WO2023159036A1 (en) * | 2022-02-16 | 2023-08-24 | The Cleveland Clinic Foundation | Amhr2-ed cancer vaccine formulations |
| WO2023192876A1 (en) * | 2022-03-28 | 2023-10-05 | Reilly Steve E | Composition to increase cellular longevity |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| EP4458968A1 (en) | 2023-05-05 | 2024-11-06 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for shaping the cellular proteome |
| CR20250529A (es) * | 2023-06-09 | 2026-01-12 | Merck Sharp & Dohme Llc | Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano |
| WO2025040709A1 (en) | 2023-08-24 | 2025-02-27 | BioNTech SE | Systems and compositions comprising highly active trans-amplifying replicases |
| WO2025051381A1 (en) | 2023-09-08 | 2025-03-13 | BioNTech SE | Methods and compositions for localized expression of administered rna |
| WO2025244961A1 (en) * | 2024-05-22 | 2025-11-27 | Merck Sharp & Dohme Llc | Processes for making stable nanoemulsion adjuvants |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA583561A (en) | 1959-09-22 | H. Edgerton William | Therapeutically valuable esters and methods for obtaining the same | |
| FR1317586A (enExample) | 1961-03-17 | 1963-05-08 | ||
| US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| IE51913B1 (en) | 1980-10-09 | 1987-04-29 | Mars G B Ltd | Thermo irreversible gelling system and edible materials based thereon |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| CA1341482C (en) | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
| US4689225A (en) | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| DK341386D0 (da) | 1986-07-18 | 1986-07-18 | Voetman Karin Glassau | Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader |
| ES2053549T3 (es) | 1986-08-11 | 1994-08-01 | Innovata Biomed Ltd | Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion. |
| US5906980A (en) | 1987-07-17 | 1999-05-25 | Hem Research Inc. | Treatment of hepatitis with mismatched dsRNA |
| US5712257A (en) | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
| WO1989004669A1 (en) | 1987-11-18 | 1989-06-01 | Chiron Corporation | Nanbv diagnostics and vaccines |
| EP0436537A4 (en) | 1988-01-29 | 1992-04-08 | Chiron Corporation | Recombinant cmv neutralizing proteins |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| HUT54896A (en) | 1989-03-17 | 1991-04-29 | Chiron Corp | Process for producing aquous diagnosticum and vaccine of nanbv |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| KR0185426B1 (ko) | 1991-06-24 | 1999-04-01 | 로버트 피. 블랙버언 | 씨형 간염 바이러스 폴리펩티드 |
| DK0608261T3 (da) | 1991-09-13 | 2003-03-17 | Chiron Corp | Sammensætninger med immunreaktivt hepatitis C virus polypeptid |
| JPH09500013A (ja) | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| JP2001503735A (ja) | 1996-07-03 | 2001-03-21 | ユニバーシティ オブ ピッツバーグ | 親水性活性試薬のためのエマルジョン処方物 |
| EP0938298B1 (en) | 1996-09-13 | 2002-12-04 | Lipoxen Technologies Limited | Liposome-based composition |
| ES2195317T3 (es) | 1997-01-30 | 2003-12-01 | Chiron Corp | Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias. |
| WO2000006123A1 (en) | 1998-07-29 | 2000-02-10 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| US6884435B1 (en) | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2295740A1 (en) | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| PT1042001E (pt) | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| JP2002521423A (ja) * | 1998-07-31 | 2002-07-16 | コリア インスティチュート オブ サイエンス アンド テクノロージ | 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子 |
| US20020142974A1 (en) | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
| US6770282B1 (en) | 1998-10-23 | 2004-08-03 | Heska Corporation | Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
| AP1891A (en) | 1999-05-06 | 2008-09-23 | The Immune Response Corp | HIV immunogenic compositions and methods. |
| WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| WO2001036599A1 (en) | 1999-11-19 | 2001-05-25 | Chiron Corporation | Microparticle-based transfection and activation of dendritic cells |
| US20030138453A1 (en) | 2000-09-28 | 2003-07-24 | O'hagan Derek | Microparticles for delivery of heterologous nucleic acids |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| CA2487274A1 (en) * | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| AU2003302226A1 (en) | 2002-09-24 | 2004-06-30 | University Of Kentucky Research Foundation | Nanoparticle-based vaccine delivery system containing adjuvant |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| AU2005259799A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory siRNA molecules and uses therefor |
| US7749520B2 (en) | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| BRPI0516974A (pt) | 2004-10-21 | 2008-09-30 | Wyeth Corp | composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis |
| FR2885813B1 (fr) | 2005-05-19 | 2008-01-11 | Oreal | Vectorisation de dsrna par des particules cationiques et leur utilisation sur modele de peau. |
| ES2385924T3 (es) | 2006-02-02 | 2012-08-03 | Allergan, Inc. | Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares |
| CA2649630C (en) | 2006-04-20 | 2016-04-05 | Silence Therapeutics Ag | Lipoplex formulations for specific delivery to vascular endothelium |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| JP5781929B2 (ja) | 2008-07-15 | 2015-09-24 | ノバルティス アーゲー | 免疫原性の両親媒性ペプチド組成物 |
| MX2011010045A (es) * | 2009-03-25 | 2011-10-11 | Novartis Ag | Composicion farmaceutica que contiene un farmaco y siarn. |
| CN101538745B (zh) * | 2009-04-22 | 2010-12-29 | 西南交通大学 | 一种可控释放基因药物的生物降解聚合物超细纤维的制备方法 |
| WO2010142660A2 (en) * | 2009-06-09 | 2010-12-16 | Novartis Ag | Drug delivery system |
| EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| WO2011076807A2 (en) * | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| JP5704163B2 (ja) | 2010-03-12 | 2015-04-22 | コニカミノルタ株式会社 | 分子間相互作用の検出方法およびその検出装置 |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| CA2804591C (en) * | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| JP6136343B2 (ja) | 2012-06-12 | 2017-05-31 | 株式会社リコー | 情報処理システム、情報処理方法、プログラム、及び記録媒体 |
| WO2020000015A1 (en) | 2018-06-29 | 2020-01-02 | Integria Healthcare (Australia) Pty Limited | Immunomodulatory compositions and uses thereof |
-
2012
- 2012-07-06 US US14/130,886 patent/US9636410B2/en active Active
- 2012-07-06 BR BR112014000235A patent/BR112014000235A8/pt not_active Application Discontinuation
- 2012-07-06 WO PCT/US2012/045845 patent/WO2013006837A1/en not_active Ceased
- 2012-07-06 CA CA2840965A patent/CA2840965C/en active Active
- 2012-07-06 AU AU2012280904A patent/AU2012280904B2/en not_active Ceased
- 2012-07-06 EP EP12743273.0A patent/EP2729124B1/en active Active
- 2012-07-06 EP EP18201788.9A patent/EP3456316A1/en not_active Withdrawn
- 2012-07-06 ES ES12743273T patent/ES2702318T3/es active Active
- 2012-07-06 MX MX2014000040A patent/MX350258B/es active IP Right Grant
- 2012-07-06 RU RU2014104094A patent/RU2649133C2/ru active
- 2012-07-06 SG SG10201605500TA patent/SG10201605500TA/en unknown
- 2012-07-06 CN CN201280033539.6A patent/CN103796639B/zh not_active Expired - Fee Related
- 2012-07-06 JP JP2014519088A patent/JP6120839B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-09 JP JP2016156141A patent/JP2016210792A/ja not_active Withdrawn
-
2017
- 2017-03-23 US US15/467,660 patent/US10183074B2/en active Active
- 2017-05-18 AU AU2017203342A patent/AU2017203342A1/en not_active Abandoned
-
2018
- 2018-12-06 US US16/212,245 patent/US11167028B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014104094A (ru) | Катионные эмульсии масло-в-воде | |
| US11965000B2 (en) | Respiratory syncytial virus (RSV) vaccine | |
| US10960070B2 (en) | Prefusion coronavirus spike proteins and their use | |
| JP2026040566A (ja) | ＳＡＲＳ－ＣｏＶ－２ワクチン | |
| Chen et al. | Blood–brain barrier-and blood–brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases | |
| US20220218815A1 (en) | Coronavirus vaccine | |
| JP2013531680A5 (enExample) | ||
| US20220378700A1 (en) | Lipid Nanoparticles and Formulations Thereof for CAR mRNA Delivery | |
| RU2468034C2 (ru) | Иммуногенные композиции и способы | |
| JP2014522840A5 (enExample) | ||
| US20220396556A1 (en) | Lipid and Lipid Nanoparticle Formulation for Drug Delivery | |
| RU2014104092A (ru) | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты | |
| CN119947747A (zh) | 流感病毒疫苗 | |
| TWI853485B (zh) | 核酸-脂質奈米粒子及使用其之方法 | |
| Jiang et al. | Specially-made lipid-based assemblies for improving transmembrane gene delivery: comparison of basic amino acid residue rich periphery | |
| US20240228549A1 (en) | Prefusion-stabilized lassa virus glycoprotein complex and its use | |
| TW202438672A (zh) | 四價流感疫苗之方法及組成物 | |
| EP4313115A1 (en) | Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof | |
| US20240374714A1 (en) | Compositions and methods for multivalent immune responses | |
| BR112021001460A2 (pt) | trímeros de glicoproteína de filovírus estabilizados | |
| JPWO2022244825A5 (enExample) | ||
| EP3586871A2 (en) | Respiratory syncytial virus (rsv) vaccine | |
| WO2026047603A1 (en) | Sars-cov-2 immunogenic compositions | |
| HK40090415A (en) | Coronavirus vaccine | |
| WO2025111442A1 (en) | Lipid nanoparticles and methods of use for dna delivery |